Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of a post-marketing surveillance study in primary care in Germany

Current Medical Research and Opinion

Volumn 18, Issue 4, 2002, Pages 229-236

  Zacher, J ^b   Schattenkirchner, M ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b NONE

Author keywords

Osteoarthritis; Pain relief; Patient satisfaction; Post marketing surveillance; Rofecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CLIMBING; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLATULENCE; GASTRITIS; GERMANY; HEADACHE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; NORMAL HUMAN; OSTEOARTHRITIS; PATIENT SATISFACTION; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIMARY MEDICAL CARE; PRURITUS; QUALITY OF LIFE; RASH; REFLUX ESOPHAGITIS; VERTIGO; WALKING; MIDDLE AGED; PRIMARY HEALTH CARE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; GERMANY; HUMAN; LACTONES; MALE; MIDDLE AGE; OSTEOARTHRITIS; PATIENT SATISFACTION; PRIMARY HEALTH CARE; PRODUCT SURVEILLANCE, POSTMARKETING; SUPPORT, NON-U.S. GOV'T; TREATMENT OUTCOME; HUMANS; MIDDLE AGED; SULFONES;

EID: 0036023528     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000796     Document Type: Article

References (18)

1. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
2. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
3. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
4. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
5. Nonsteroidal anti-inflammatory drug gastropathy
6. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
7. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study
8. Kosequenzen und kosten der NSA-Gastropathie in Deutschland
9. Validation study of WOMAC: A health status instrument for measuring clinically important patient-relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee
10. Patient and physician satisfaction with rofecoxib in osteoarthritis: Results of the EVA (Experience with VIOXX in Arthritis) survey
11. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial
12. Effect of rofecoxib, celecoxib, and naproxen on blood pressure and urinary sodium excretion in elderly volunteers
13. Treating osteoarthritis in practice - The TOP study
14. Less use of gastrointestinal (GI) protective agents and GI-related procedures with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study
15. Less healthcare resource utilization for perforations, ulcers and bleeds with rofecoxib vs. naproxen in the VIGOR (VIOXX GI Outcomes Research) Study
16. Economic burden of NSAID-induced gastropathy in Sweden